Parkinson’s disease (PD) is caused by progressive neurodegeneration and characterised by motor dysfunction. Neurodegeneration of dopaminergic neurons also causes aberrations within the cortico-striato-thalamo-cortical (CSTC) circuit, which has been hypothesised to lead to non-motor symptoms such as depression. Individuals with PD have both lower synaptic density and changes in neuronal metabolic function in the basal ganglia, as measured using [11C]UCB-J and [18F]FDG positron emission tomography (PET), respectively. However, the two radioligands have not been directly compared in the same PD subject or in neurodegeneration animal models. Here, we investigate [11C]UCB-J binding and [18F]FDG uptake in the CSTC circuit following a unilateral d...
Objectives: Rat models of Parkinson’s disease (PD), such as lesioned rats with 6-hydroxydopamine (6-...
Because of the progressive loss of nigro-striatal dopaminergic terminals in Parkinson’s disease (PD)...
Position emission tomography (PET) provides non-invasive quantifications of brain glucose metabolism...
Parkinson’s disease (PD) is caused by progressive neurodegeneration and characterised by motor dysfu...
Carbon-11 labeled dihydrotetrabenazine (11C-DTBZ) binds to the vesicular monoamine transporter 2 and...
Parkinson´s disease (PD) is characterized by nigro-striatal loss and dopaminergic striatal depletion...
Parkinson´s disease(PD) is characterize by a progressive death of dopaminergic neurons in the substa...
ABSTRACT – EMIM 2018 Introduction The pathological features of Parkinson’s Disease (PD) are driven...
Abstract – NRM2018 Introduction The pathological features of Parkinson’s Disease (PD) are mainly d...
Dopamine transporter (DAT) and glucose metabolism imaging have been applied in the diagnosis of Park...
We characterized the unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rat, a well-known acute model ...
ABSTRACT - NECTAR 2018 Parkinson’s Disease (PD) is characterized by dopaminergic neuronal loss in t...
Neurodegenerative disorders comprise a group of conditions, including Parkinson’s and Alzheimer’s di...
Background: Rat models of Parkinson’s disease (PD), such as lesioned rats with 6-hydroxydopamine (6-...
Because of the progressive loss of nigro-striatal dopaminergic terminals in Parkinson’s disease (PD)...
Objectives: Rat models of Parkinson’s disease (PD), such as lesioned rats with 6-hydroxydopamine (6-...
Because of the progressive loss of nigro-striatal dopaminergic terminals in Parkinson’s disease (PD)...
Position emission tomography (PET) provides non-invasive quantifications of brain glucose metabolism...
Parkinson’s disease (PD) is caused by progressive neurodegeneration and characterised by motor dysfu...
Carbon-11 labeled dihydrotetrabenazine (11C-DTBZ) binds to the vesicular monoamine transporter 2 and...
Parkinson´s disease (PD) is characterized by nigro-striatal loss and dopaminergic striatal depletion...
Parkinson´s disease(PD) is characterize by a progressive death of dopaminergic neurons in the substa...
ABSTRACT – EMIM 2018 Introduction The pathological features of Parkinson’s Disease (PD) are driven...
Abstract – NRM2018 Introduction The pathological features of Parkinson’s Disease (PD) are mainly d...
Dopamine transporter (DAT) and glucose metabolism imaging have been applied in the diagnosis of Park...
We characterized the unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rat, a well-known acute model ...
ABSTRACT - NECTAR 2018 Parkinson’s Disease (PD) is characterized by dopaminergic neuronal loss in t...
Neurodegenerative disorders comprise a group of conditions, including Parkinson’s and Alzheimer’s di...
Background: Rat models of Parkinson’s disease (PD), such as lesioned rats with 6-hydroxydopamine (6-...
Because of the progressive loss of nigro-striatal dopaminergic terminals in Parkinson’s disease (PD)...
Objectives: Rat models of Parkinson’s disease (PD), such as lesioned rats with 6-hydroxydopamine (6-...
Because of the progressive loss of nigro-striatal dopaminergic terminals in Parkinson’s disease (PD)...
Position emission tomography (PET) provides non-invasive quantifications of brain glucose metabolism...